Novo Nordisk objects to proposed reimbursement change for its fast-acting insulin in Denmark
Novo Nordisk does not concur with an assessment from the Danish Medicines Agency's Reimbursement Committee, which could result in the pharmaceutical company's fast-acting insulin Fiasp receiving conditional reimbursement instead of general reimbursement status.
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen
The Reimbursement Committee, which advises the the Danish Medicines Agency on drug reimbursements, has proposed a reassessment of the drug Fiasp, and the company behind the product, Novo Nordisk, has voiced its opposition to the change.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk Q3 profit surpasses USD 1.8bn
For subscribers
WHO adds Novo Nordisk insulin to essential medicine lists
For subscribers
.jpg&w=384&q=75)
